Literature DB >> 18475655

IL-4 induces cAMP and cGMP in human monocytic cells.

B Dugas1, N Paul-Eugene, K Yamaoka, C Amirand, C Damais, J P Kolb.   

Abstract

Human monocytes, preincubated with IFN-gamma respond to IL-4 by a cGMP increase through activation of an inducible NO synthase. Here, IL-4 was found to induce an accumulation of cGMP (1 - 3 min) and cAMP (20 - 25 min) in unstimulated monocytes. This was impaired with NOS inhibitors, but also with EGTA and calcium/calmodulin inhibitors. These results suggest that: (1) IL-4 may stimulate different NOS isoforms in resting and IFN-gamma activated monocytes, and (2) cAMP accumulation may be partially dependent on the NO pathway. By RT-PCR, a type III constitutive NOS mRNA was detected in U937 monocytic cells. IL-4 also increased the [Ca(2+)](i) in these cells. Different NOS may thus be expressed in monocytic cells depending on their differentiation and the signals they receive.

Entities:  

Year:  1995        PMID: 18475655      PMCID: PMC2365639          DOI: 10.1155/S0962935195000482

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  44 in total

Review 1.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

2.  Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes.

Authors:  A A te Velde; R J Huijbens; K Heije; J E de Vries; C G Figdor
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

3.  IL-4 decreases Fc gamma R membrane expression and Fc gamma R-mediated cytotoxic activity of human monocytes.

Authors:  A A te Velde; R J Huijbens; J E de Vries; C G Figdor
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

4.  Interleukin 4 down-regulates the expression of CD14 in normal human monocytes.

Authors:  R P Lauener; S M Goyert; R S Geha; D Vercelli
Journal:  Eur J Immunol       Date:  1990-11       Impact factor: 5.532

5.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.

Authors:  S Endres; H J Fülle; B Sinha; D Stoll; C A Dinarello; R Gerzer; P C Weber
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

6.  Interleukin-4 receptor regulation in human monocytic cells.

Authors:  H de Wit; D W Hendriks; M R Halie; E Vellenga
Journal:  Blood       Date:  1994-07-15       Impact factor: 22.113

7.  Interleukin-4 stimulates cGMP production by IFN-gamma-activated human monocytes. Involvement of the nitric oxide synthase pathway.

Authors:  J P Kolb; N Paul-Eugene; C Damais; K Yamaoka; J C Drapier; B Dugas
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

8.  Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction.

Authors:  S M Zurawski; F Vega; B Huyghe; G Zurawski
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

9.  IL-4 and IL-13 induce Lsk, a Csk-like tyrosine kinase, in human monocytes.

Authors:  T Musso; L Varesio; X Zhang; T K Rowe; P Ferrara; J R Ortaldo; J J O'Shea; D W McVicar
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

10.  An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors.

Authors:  G Aversa; J Punnonen; B G Cocks; R de Waal Malefyt; F Vega; S M Zurawski; G Zurawski; J E de Vries
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  1 in total

1.  Bitter taste receptors stimulate phagocytosis in human macrophages through calcium, nitric oxide, and cyclic-GMP signaling.

Authors:  Indiwari Gopallawa; Jenna R Freund; Robert J Lee
Journal:  Cell Mol Life Sci       Date:  2020-03-14       Impact factor: 9.261

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.